Stentys lands new indications for its self-apposing stent, now marketable for a patient population that represents 10% of all PCIs in Europe.
Regulators in Europe handed Stentys SA (EPA:STNT) expanded indications for its self-apposing stent, opening up new potential patient populations.
The Stentys treatment for acute myocardial infarction can now be used in patients with trickier cases, such as those with tapered, dilated or very large vessels or those with bypass grafts. E.U. healthcare regulators also lifted certain contraindications on the device, such as for chronic total occlusions and left main bifurcations.
